AnaptysBio Inc (ANAB) USD0.001

Sell:$24.66Buy:$24.70$0.14 (0.57%)

NASDAQ:2.24%
Market closed | Prices delayed by at least 15 minutes
Sell:$24.66
Buy:$24.70
Change:$0.14 (0.57%)
Market closed | Prices delayed by at least 15 minutes
Sell:$24.66
Buy:$24.70
Change:$0.14 (0.57%)
Market closed | Prices delayed by at least 15 minutes

Company Information

About this company

AnaptysBio, Inc. is a clinical-stage biotechnology company. The Company is focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. The Company’s lead program, Rosnilimab, is a depleter and agonist targeting PD-1+ T cells, is in a Phase IIb trial for the treatment of rheumatoid arthritis and in a Phase II trial for the treatment of ulcerative colitis. The Company’s pipeline also includes ANB033, a CD122 antagonist, and ANB101, a blood dendritic cell antigen 2 (BDCA2) modulator, in Phase I trials. It has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) and a TIM-3 antagonist (cobolimab, GSK4069889). Rosnilimab is an IgG1 antibody that directly targets PD-1+ T cells, resulting in their depletion or agonism, impacting pathogenic drivers of autoimmune and inflammatory diseases.

Key people

Daniel R. Faga
President, Chief Executive Officer, Director
Dennis M. Mulroy
Chief Financial Officer
Paul F. Lizzul
Chief Medical Officer
Eric Joseph Loumeau
Chief Legal Officer
John A. Orwin
Non-Executive Independent Chairman of the Board
Dennis Fenton
Independent Director
Rita Jain
Independent Director
Magda Marquet
Independent Director
Oleg Nodelman
Independent Director
Click to see more

Key facts

  • EPIC
    ANAB
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US0327241065
  • Market cap
    $733.92m
  • Employees
    136
  • Shares in issue
    29.38m
  • Exchange
    NASDAQ
  • Index
    TR Equity United States Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.